Modality
Radioligand
MOA
TYK2i
Target
Nectin-4
Pathway
PD-1/PD-L1
RettCrohn'sCF
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
~Feb 2017
→ ~May 2018
Phase 3
Aug 2018
→ Aug 2027
Phase 3Current
NCT08780253
683 pts·Crohn's
2018-08→2025-01·Active
NCT07658278
2,370 pts·Crohn's
2024-11→2027-08·Active
NCT07188287
2,271 pts·Rett
2025-02→2026-06·Recruiting
5,324 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-01-251.2y agoPh3 Readout· Crohn's
2026-06-263mo awayPh3 Readout· Rett
2027-08-221.4y awayPh3 Readout· Crohn's
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Active
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2025-01-25 · 1.2y ago
Crohn's
Ph3 Readout
2026-06-26 · 3mo away
Rett
Ph3 Readout
2027-08-22 · 1.4y away
Crohn's
RecruitingActive|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08780253 | Phase 3 | Crohn's | Active | 683 | VA |
| NCT07658278 | Phase 3 | Crohn's | Active | 2370 | NT-proBNP |
| NCT07188287 | Phase 3 | Rett | Recruiting | 2271 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin |